CAG
AMPH icon

Csenge Advisory Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Csenge Advisory Group’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,672
Closed -$413K – 710
2023
Q4 		$413K Buy
+6,672
New +$350K 0.03% 452
2018
Q4 		– Sell
-10
Closed – – 255
2018
Q3 		$0 Buy
+10
New +$178 ﹤0.01% 1026

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Csenge Advisory Group's AMPH Position: Q1 2024 in Review

Csenge Advisory Group sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 6,672 shares — an estimated $413K sold.

Csenge Advisory Group first reported a position in AMPH in Q3 2018 and held it in 2 quarters. The position peaked at $413K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Csenge Advisory Group reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Csenge Advisory Group sold 6,672 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $413K.
  • Csenge Advisory Group first reported a position in Amphastar Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Csenge Advisory Group's Amphastar Pharmaceuticals position peaked at $413K in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Csenge Advisory Group's 13F filing for Q1 2024, filed 3 May 2024.